Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06302569
Title Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT)
Acronym REPRINT
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Giuseppe Procopio
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA


No variant requirements are available.